Boundless Bio, Inc. 8-K

What Happened

• On March 9, 2026 Boundless Bio, Inc. (BOLD) issued a press release announcing its fourth-quarter and full-year financial results for the period ended December 31, 2025; the press release is attached to the Form 8-K as Exhibit 99.1. The Form 8-K notes the release is furnished (not “filed”) under General Instruction B.2 of Form 8-K.
• Separately, effective March 3, 2026, director Christine Brennan, Ph.D., notified the company of her resignation from the Board to assume a new role at Johnson & Johnson Development Corporation; the company states her resignation was not due to any disagreement with Boundless Bio.

Key Details

• Filing date: March 9, 2026 (Form 8-K).
• Reporting period for results: Quarter and full year ended December 31, 2025.
• Exhibit included: Exhibit 99.1 — press release announcing the financial results (furnished, not filed).
• Board change: Christine Brennan, Ph.D., resigned effective March 3, 2026; resignation unrelated to company disagreements.

Why It Matters

• Earnings/financial results: The press release contains the company’s latest quarterly and annual results (revenue, net loss, cash position and related metrics are expected there); investors should read Exhibit 99.1 to see actual figures and any management commentary on performance or outlook. Furnished (vs. filed) status limits certain legal exposure under Section 18.
• Governance: A director departure can affect board composition and oversight. Because the company says the resignation is for a new job and not due to disagreement, this reduces governance red-flag risk, but investors may want to monitor any subsequent board appointments or proxy updates.

Next steps for investors: review the March 9, 2026 press release (Exhibit 99.1) for the specific financial results and management commentary, and watch for follow-up filings or announcements about any new board members.